Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches
Open accessThe DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Mitochondrial dysfunctions are central players in Alzheimer’s disease (AD). In addition, impairments in mitophagy, the process of selective mitochondrial degradation by autophagy leading to a gradual accumulation of defective mitochondria, have also been reported to occur in AD. We provide an updated overview of the recent discoveries and advancements on mitophagic molecular dysfunctions in AD-derived fluids and cells as well as in AD brains. We discuss studies using AD cellular and animal models that have unraveled the contribution of relevant AD-related proteins (Tau, Aβ, APP-derived fragments and APOE) in mitophagy failure. In accordance with the important role of impaired mitophagy in AD, we report on various therapeutic strategies aiming at stimulating mitophagy in AD and we summarize the benefits of these potential therapeutic strategies in human clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“PINK1/parkin cascades related to Aβ, APP-CTFs, tau, and the APOE4 isoform could lead to the accumulation of damaged mitochondria.306”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [306]
The cited source says what the claim attributes to it.
In the citing paper
“in vitro studies have indicated that this mitochondrial dysfunction partly results from a blockade of mitophagy owing to APOE4-mediated lysosomal dysfunction, which leads to an accumulation of damaged and dysfunctional mitochondrial in APOE4 carriers167–169.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [168]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952 · cited 1×
“Familial AD (FAD) form is linked to monogenic mutations in the Amyloid Precursor Protein (APP) gene and in Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) genes, with the latter two encoding the catalytic core of the γ-secretase complex [3].”
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · cited 1×
“Major clinical symptoms of the disease are a decline of cognition and memory capacities attributed in sporadic AD (SAD) to environmental and/or genetic susceptibility factors, the first discovered being the Apolipoprotein (APOE) gene [2].”
Fang, E. F., Hou, Y., Palikaras, K., Adriaanse, B. A., Kerr, J. S., Yang, B., Lautrup, S., Hasan-Olive, M. M., Caponio, D., Dan, X., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0332-9 · Cited by 1,740 · cited 11×
“ND TEM ↑ Number of damaged mitochondria [16]”
InfluentialInduction of autophagy by spermidine promotes longevity
Eisenberg, T., Knauer, H., Schauer, A., Büttner, S., Ruckenstuhl, C., Carmona-Gutierrez, D., Ring, J., Schroeder, S., Magnes, C., Antonacci, L., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1975 · Cited by 1,680 · cited 1×
“_Spermidine is a small and natural organic molecule known to prolong lifespan of yeast, flies, nematodes and mice by upregulating autophagy [85, 86].”
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“This was suggested by the accumulation of mitDNA and proteins in the cytoplasm, as well as in autophagic vacuoles (AVs) in AD neurons featuring increased oxidative damages [10].”
Lee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.008 · Cited by 1,212
Ryu, D., Mouchiroud, L., Andreux, P. A., Katsyuba, E., Moullan, N., Nicolet-dit-Félix, A. A., Williams, E. G., Jha, P., Lo Sasso, G., Huzard, D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4132 · Cited by 1,105 · cited 1×
“Pharmacological strategies _Urolithin A (UA), derived from ellagitannins polyphenols, is known to induce beneficial effects on mitochondrial homeostasis and functions through the stimulation of mitophagy in nematodes and mammals [67].”
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms
Kerr, J. S., Adriaanse, B. A., Greig, N. H., Mattson, M. P., Cader, M. Z., Bohr, V. A., & Fang, E. F. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.01.002 · Cited by 870 · cited 1×
“mimicking familial forms of AD and in the brains of SAD patients, have then led to the hypothesis that impaired mitophagy is an important aspect of the disease, and could lie both upstream and downstream of Aβ and Tau in a vicious circle ultimately causing synaptic dysfunctions and cognitive deficits [9].”
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“306 The accumulation of A β and increased p-tau, synaptic dysfunction, in turn, negatively regulate mitophagic activity, accelerating the pathological progression of AD.”
BackgroundFree radicals and their impact on health and antioxidant defenses: a review
Chandimali, N., Bak, S. G., Park, E. H., Lim, H.-J., Won, Y.-S., Kim, E.-K., Park, S.-I., & Lee, S. J. (2025) · Cell Death Discovery · doi:10.1038/s41420-024-02278-8 · Cited by 669
“Additionally, mitochondrial DNA mutations and reduced mitophagy exacerbate mitochondrial dysfunction and contribute to the progression of AD [158].”
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J.-Z. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 199
“Simultaneously, the mitochondrial membrane potential is increased with impaired energy production and inhibition of mitophagy [319–321].”
BackgroundMitochondrial dysfunction in Alzheimer’s disease
D’Alessandro, M. C. B., Kanaan, S., Geller, M., Praticò, D., & Daher, J. P. L. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102713 · Cited by 192
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
Metadata
- Authors
- Mary, A., Eysert, F., Checler, F., & Chami, M.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Chami, Mounia
- Venue
- Molecular Psychiatry
- Published
- 2022-06-03
- Volume
- 28
- Issue
- 1
- Pages
- 202-216
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC9812780
- OpenAlex
- W4281929193
- Cited by
- 244
- References
- 113
- Citations by year
- 2026: 56 · 2025: 92 · 2024: 55 · 2023: 34 · 2022: 7
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Funders
- Fondation Vaincre Alzheimer
- LABEX (excellence laboratory, program investment for the future) DISTALZ
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- mitophagy, Alzheimer's disease, mitochondrial dysfunction, autophagy, tau protein, amyloid-beta, apolipoprotein E, treatment options, clinical trials
- MeSH terms
- Alzheimer Disease, Animals, Autophagy, Disease Models, Animal, Humans, Mitochondria, Amyloid beta-Peptides, Mitophagy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches. https://app.cochat.ai/papers/10.1038/s41380-022-01631-6
- The paper
- Mary, A., Eysert, F., Checler, F., & Chami, M. (2023). Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01631-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.